OMCLNasdaqElectronic ComputersUS GAAP · USD

Omnicell, Inc

Omnicell, Inc. designs and sells medication management technology for healthcare providers, including automated dispensing systems, robotics, smart devices, software workflows, and related services. The company serves hospitals, health systems, pharmacies, and specialty pharmacy customers primarily in the United States, with additional activity in Canada and other international markets.

Kysy yhtiöstä
Liikevaihto1 185milj. USD
+6,5 %v/v
Liikevoitto (EBIT)5,2milj. USD
+1 431,2 %v/v
EBIT-marginaali0,4%
+0,4 %-yks.v/v
Nettotulos2,1milj. USD
−83,6 %v/v
Vapaa kassavirta86,9milj. USD
−42,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50005001 0001 500milj. USD2020: 892 milj. USD2020: EBIT 36 milj. USD20202021: 1 132 milj. USD2021: EBIT 90 milj. USD20212022: 1 296 milj. USD2022: EBIT −2,3 milj. USD20222023: 1 147 milj. USD2023: EBIT −35 milj. USD20232024: 1 112 milj. USD2024: EBIT 0,34 milj. USD20242025: 1 185 milj. USD2025: EBIT 5,2 milj. USD20251 1855,2
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Omnicell, Inc

Liiketoiminta

Osuus liikevaihdosta
Connected devices, software licenses, and other45 %

Nonrecurring automation hardware, software licenses, and related product revenue.

Consumables15 %

Recurring product consumables used with dispensing and medication management systems.

Technical services20 %

Recurring support, maintenance, and implementation-related services.

SaaS and Expert Services20 %

Subscription software and specialized pharmacy services including EnlivenHealth and 340B offerings.

Tuotteet

Raportoitu · osuus liikevaihdosta
47,7%21,9%21,9%8,5%FY2025100 %
  • Connected Devices Software Licenses and Other47,7 %
  • Technical Services21,9 %
  • Saa S and Expert Services21,9 %
  • Consumables8,5 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Omnicell sells to hospitals, health systems, outpatient pharmacies, provider groups, and federally qualified health centers. Its solutions are used by pharmacists and nurses to automate medication handling, improve inventory control, and support compliance across inpatient and outpatient care settings.

Hospital and health system solutions

Hospitals and integrated delivery networks buy dispensing automation, software, and services to standardize medication workflows and improve control.

Outpatient pharmacy solutions

Outpatient and retail pharmacy customers use software, devices, and services to manage prescriptions, adherence, and operational efficiency.

Specialty pharmacy services

Provider groups, FQHCs, and health systems use specialty pharmacy access, payer contracting, and LDD support.

340B and optimization services

Healthcare providers buy 340B and inventory optimization tools to manage reimbursement, compliance, and supply chain complexity.

Strategia

Omnicell’s strategy centers on the Autonomous Pharmacy vision: combining automation, software, services, and analytics to reduce manual medication handling and improve pharmacy operations. The company is also expanding recurring revenue through SaaS, expert services, and specialty pharmacy offerings while continuing to develop its platform through acquisitions and product innovation.

Autonomous Pharmacy platform expansionKeskipitkä aikaväli

A unified platform increases customer dependence and supports cross-selling across hardware, software, and services.

Shift toward recurring revenueKeskipitkä aikaväli

Subscriptions and services can improve revenue visibility and deepen customer relationships.

Broaden specialty pharmacy and 340B capabilitiesKeskipitkä aikaväli

These offerings extend the platform into higher-need pharmacy workflows and reimbursement complexity.

Selective acquisitions and product developmentPitkä aikaväli

Technology and product additions can expand the installed base and address adjacent workflows.

Maantiede

Q1/2026

Omnicell generates the large majority of its revenue in the United States, and its sales force is organized around U.S. and Canadian customer segments. The company also serves healthcare facilities in other countries, but its operating footprint and revenue exposure remain concentrated in North America.

USA90 %
Other countries (US filing)10 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Omnicell faces demand, competitive, regulatory, and technology risks tied to healthcare automation and pharmacy services. Its business is also exposed to supply-chain constraints, cybersecurity, customer credit and lease financing risk, and the challenge of maintaining access to specialty drugs and pharmacy networks.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Customer demand and adoption risk1Competitive pressure2Healthcare regulatory and compliance risk3Cybersecurity and data security risk4Supply chain and component availability risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Customer demand and adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Hospitals and pharmacies may delay or reduce purchases of automation and services in weak conditions.

    Kohdistuu: Medication management solutions and related services

  2. Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company competes against larger healthcare technology and pharmacy automation vendors.

    KohdistuuHospital and health system solutionsOutpatient pharmacy solutions
  3. Healthcare regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Products and services operate in a heavily regulated environment with privacy, fraud, and anti-kickback exposure.

    KohdistuuHealthcarePrivacyData protectionGovernment programs
  4. Cybersecurity and data security riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Software and connected devices create exposure to breaches, outages, and service disruption.

    KohdistuuSaaSExpert servicesConnected devices
  5. Specialty pharmacy access riskVaikutus: Korkea

    Loss of access to limited distribution drugs or pharmacy networks could reduce customer value.

    Kohdistuu: Specialty Pharmacy Services

  6. Supply chain and component availability riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Hardware products depend on raw materials, components, and third-party vendors.

    Kohdistuu: Connected devices and automation systems

Kysy Clarifolta: Omnicell, Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

The company sells nonrecurring products and recurring services, so timing of recognition affects comparability.

Vaikutus: Hardware, software licenses, consumables, SaaS, and expert services

Inventory

Automation hardware requires component inventory and valuation judgments.

Vaikutus: Gross margin and write-down risk

Goodwill and intangible assets

Prior acquisitions created significant goodwill and intangibles that must be tested for impairment.

Vaikutus: Potential noncash impairment charges

Income taxes

Tax estimates can vary with jurisdictional mix and uncertain tax positions.

Vaikutus: Quarterly earnings volatility

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

OMNIQ Corp.

OMQS · Services-Computer Integrated Systems Design

OmniAb, Inc.

OABIW · Services-Commercial Physical & Biological Research

Insulet Corporation

PODD · Surgical & Medical Instruments & Apparatus

Omnicom Group Inc

OMC · Services-Advertising Agencies

Stimcell Energetics Inc.

STME · Surgical & Medical Instruments & Apparatus

INVO Fertility, Inc.

IVF · Surgical & Medical Instruments & Apparatus

Päivitetty: 24.9.2026

Omnicell, Inc (OMCL) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo